

## Consult Report

Comprehensive EHR documentation of patient medical histories can help support efforts to avoid failed prior authorization (PA) requests. Once a prescriber has determined the appropriate patient for PRALUENT, EHR medical history reports can help support a prior authorization request. Knowledge of payer utilization management criteria and patient medical history reports can help to reduce submission of patients who are not PA criteria eligible.

eClinical Works supports the ability to print a Consult Report, which may assist in the completion of payer PA forms. Available clinical data that can be listed on the Consult Report include diagnosis, current and prior medications, lab values, and other clinical or patient demographic information. For PRALUENT, PA criteria may require a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), maximally tolerated statin therapy (eg, atorvastatin 40 mg/day), and LDL-C  $\geq 70$  mg/dL or  $\geq 100$  mg/dL, depending on insurance.

## INDICATIONS AND USAGE

- PRALUENT is a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C
- The effect of PRALUENT on cardiovascular morbidity and mortality has not been determined

## IMPORTANT SAFETY INFORMATION

- PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization

Please see accompanying full [Prescribing Information](#)



## To Create a Consult Report:

After a patient has been identified by a prescriber as appropriate for treatment with PRALUENT, a Consult Report may be printed to support PA requirements. The following steps illustrate how create a Consult Report containing clinical and patient demographic information necessary to complete a prior authorization form.

1. From the patient's charts, navigate to the Patient Hub, Progress Notes. Choose the appropriate **progress note**
2. From Fax dropdown, select **Fax Consult Notes**
3. In the Consult Notes window, select **Note Type**, and click **Consult Report**. Choose desired **Note Sections**

The image displays two overlapping screenshots of the 'Consult Notes' window in eClinicalWorks. Both windows show the 'Note Style' dropdown set to 'Modern II'. The left window has the 'Note Selections' checkbox checked, and a list of checkboxes for various clinical sections: CC, HPI, Current Medication (checked), Medical History (checked), Allergies (checked), Surgical History, Hospitalization, Family History (checked), Social History, ROS, Vitals (checked), Examination, Physical Exam, Assessment (checked), Therapy Assessment, Treatment, Procedures, Immunizations, and XRay. Below this list are radio buttons for 'Include Cover Letter', 'Consult Report' (selected), and 'Consult Request'. A 'Fax' button is at the bottom. The right window has the 'Note Selections' checkbox checked, and a scrollable list of checkboxes: Assessment (checked), Therapeutic, Therapy Assessment, Treatment, Procedures, Immunizations, XRay, Labs (checked), Gyn History, Preventive Medicine, OB history, Next Appointment, Procedure Codes, Past Orders (checked), Disposition, Vision Examination, Disposition & Communication, Problem List (checked), Therapeutic Injections (checked), and Images. Below this list are radio buttons for 'Include Cover Letter', 'Consult Report', and 'Consult Request' (selected). 'Fax' and 'Cancel' buttons are at the bottom.

## IMPORTANT SAFETY INFORMATION

- Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve

Please see accompanying full [Prescribing Information](#)

4. Click **Fax** to display a preview window. Click **Print**

## Current Medications

Praluent 75 mg/mL injection  
Lipitor 40 mg oral tablet

## Active Problem List

E78.0 Hypercholesterolemia  
I70.0 Atherosclerosis

## Past Medical History

Percutaneous transluminal coronary angioplasty 2 years ago (left anterior descending artery)

## Family History

## Allergies

## Vital Signs

BMI = 30

## Past Orders

### Lab: Cholesterol

Total Cholesterol 226 mg/dL  
LDL-C 130 mg/dL  
HDL-C 40 mg/dL  
Non-HDL-C 186 mg/dL  
Triglycerides 280 mg/dL

## IMPORTANT SAFETY INFORMATION

- The most commonly occurring adverse reactions ( $\geq 5\%$  of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza

Please see accompanying full [Prescribing Information](#)



**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL  
Redefining Possible

## INDICATIONS AND USAGE

- PRALUENT® (alirocumab) is a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C
- The effect of PRALUENT on cardiovascular morbidity and mortality has not been determined

## IMPORTANT SAFETY INFORMATION

- PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization
- Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
- The most commonly occurring adverse reactions ( $\geq 5\%$  of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza
- Local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo
- The once-monthly (Q4W) 300 mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75 mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms
- Neurocognitive events were reported in 0.8% of patients treated with PRALUENT and 0.7% of patients treated with placebo. Confusion or memory impairment were reported more frequently by those treated with PRALUENT (0.2% for each) than in those treated with placebo ( $<0.1\%$  for each)
- Liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo
- The most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus  $<0.1\%$ )
- PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT

Please see accompanying full [Prescribing Information](#)



©2017 Sanofi and Regeneron Pharmaceuticals, Inc.  
All rights reserved. December 2017 SAUS.PRL.17.12.9337

